Ariad Sues Amgen, Wyeth Over Enbrel

Law360, New York (April 16, 2007, 12:00 AM EDT) -- Expanding an already contentious biotechnology dispute, drug maker Ariad Pharmaceuticals Inc. has filed a new patent infringement lawsuit against rivals Amgen Inc. and Wyeth over Amgen's popular anti-arthritis drugs, Enbrel and Kineret.

Filed Friday in the U.S. District Court for the District of Delaware, the lawsuit accuses Amgen and Wyeth of trampling Ariad’s patent for cell-signaling technology, which was issued in 2002 and expires in 2019.

The lawsuit was filed one year after Amgen issued a preemptive strike against Ariad in the same court. While the...
To view the full article, register now.